Status:
COMPLETED
Titration Study of ABX-1431
Lead Sponsor:
Abide Therapeutics
Conditions:
Post Herpetic Neuralgia
Diabetic Peripheral Neuropathy
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is designed to identify a titration regimen of ABX-1431 in adults with neuropathic pain with satisfactory tolerability to central nervous system (CNS) adverse events (AEs). During the cours...
Detailed Description
This is a double-blind, placebo-controlled, optimized titration study of ABX-1431 HCl. The study will explore whether patients experiencing ABX-1431-related CNS AE accommodate or become tolerant to th...
Eligibility Criteria
Inclusion
- Key
- Patient is a male or female over the age of 18 years of age at the Screening Visit.
- Patient has a peripheral neuropathic pain in one of the following diagnostic groups that is persistent for \> 3 months
- Post-herpetic neuralgia
- Diabetic peripheral neuropathy
- Small fiber neuropathy
- Post-traumatic neuropathic pain
- Patient's median NRS-11 pain intensity score must be ≥ 4 during the baseline period
- If a patient enters the trial on daily background neuropathic pain medications, then the patient must be on stable dose of medications for at least 30 days before enrollment and throughout the study.
- Patient is able to understand and comply with the protocol procedures for the entire trial and must give written informed consent.
- Men and Women must agree to a medically approved contraceptive regimen.
- Key
Exclusion
- Patient is taking potent cytochrome P450 3A4/5 inducers or inhibitors
- Patient has received injection therapies (e.g., botulinum toxin, anesthetic or nerve block) or transcutaneous electrical stimulation to control pain in the past 60 days
- Patient has evidence of alcohol, drug or chemical abuse in the year before the Screening Visit.
- Patient is a lactating or pregnant female or a female who intends to become pregnant within 90 days following the last dose of investigational product.
- Patient has specific laboratory abnormalities
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
October 2 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 7 2019
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT03447756
Start Date
October 2 2017
End Date
May 7 2019
Last Update
July 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Republican Clinical Hospital
Chisinau, Moldova, MD-2025